EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013–2023)

Shriefa Almutairi iD, Hanin Moh'd Kalloush, Nour A Manoon, Sanaa K Bardaweel iD

Molecules · 21.07.2023 · 28 (14) · 5567

DOI: 10.3390/molecules28145567 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 21.07.2023. Verfasst von Shriefa Almutairi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Jordan. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 123-mal zitiert (Crossref) und nennt 231 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Matrix metalloproteinases (MMPs) are identifiable members of proteolytic enzymes that can degrade a wide range of proteins in the extracellular matrix (ECM). MMPs can be categorized into six groups based on their substrate specificity and structural differences: collagenases, gelatinases, stromelysins, matrilysins, metalloelastase, and membrane-type MMPs. MMPs have been linked to a wide variety of biological processes, such as cell transformation and carcinogenesis. Over time, MMPs have been evaluated for their role in cancer progression, migration, and metastasis. Accordingly, various MMPs have become attractive therapeutic targets for anticancer drug development. The first generations of broad-spectrum MMP inhibitors displayed effective inhibitory activities but failed in clinical trials due to poor selectivity. Thanks to the evolution of X-ray crystallography, NMR analysis, and homology modeling studies, it has been possible to characterize the active sites of various MMPs and, consequently, to develop more selective, second-generation MMP inhibitors. In this review, we summarize the computational and synthesis approaches used in the development of MMP inhibitors and their evaluation as potential anticancer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsHumansMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesExtracellular Matrix

Stichwörter der Autor:innen

anticancer activityextra-cellular matrix remodelinginhibitorsmatrix metalloproteinases (MMPs)

Substanzen

Matrix Metalloproteinase InhibitorsMatrix MetalloproteinasesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Jordan.
  • Department of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan.

ORCID-Profile: Shriefa Almutairi, Sanaa K Bardaweel

Zitieren

APA

Almutairi, S., Kalloush, H. M., Manoon, N. A., & Bardaweel, S. K. (2023). Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013–2023). Molecules, 28(14), 5567. https://doi.org/10.3390/molecules28145567

Vancouver

Almutairi S, Kalloush HM, Manoon NA, Bardaweel SK. Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013–2023). Molecules. 2023;28(14):5567. doi:10.3390/molecules28145567

BibTeX
@article{Almutairi2023,
  author = {Almutairi, Shriefa and Kalloush, Hanin Moh'd and Manoon, Nour A and Bardaweel, Sanaa K},
  title = {Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013–2023)},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {14},
  pages = {5567},
  doi = {10.3390/molecules28145567}
}
Kostenlos starten →